Retraction Notice to: Coordinated Silencing of MYC-Mediated miR-29 by HDAC3 and EZH2 as a Therapeutic Target of Histone Modification in Aggressive B-Cell Lymphomas (Cancer Cell (2012) 22(4) (506–523), (S1535610812003923), (10.1016/j.ccr.2012.09.003));Coordinated Silencing of MYC-Mediated miR-29 by HDAC3 and EZH2 as a Therapeutic Target of Histone Modification in Aggressive B-Cell Lymphomas

Cancer Cell

Volumn 22, Issue 4, 2012, Pages 506-523

  Zhang, Xinwei ^a,b   Zhao, Xiaohong ^a   Fiskus, Warren ^c   Lin, Jianhong ^d   Lwin, Tint ^a   Rao, Rekha ^c   Zhang, Yizhuo ^b   Chan, John C ^e   Fu, Kai ^e   Marquez, Victor E ^f   Chen Kiang, Selina ^g   Moscinski, Lynn C ^a   Seto, Edward ^a   Dalton, William S ^a   Wright, Kenneth L ^a   Sotomayor, Eduardo ^a   Bhalla, Kapil ^c   Tao, Jianguo ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b KEY LABORATORY OF CANCER PREVENTION AND THERAPY   (China)

^c UNIVERSITY OF KANSAS CANCER CENTER   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^f NATIONAL CANCER INSTITUTE   (United States)

^g WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COREPRESSOR PROTEIN; HISTONE DEACETYLASE 3; MICRORNA; MICRORNA 26A; MICRORNA 29; MICRORNA 494; MYC PROTEIN; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG;

ARTICLE; B CELL LYMPHOMA; CANCER INHIBITION; CONTROLLED STUDY; GENE EXPRESSION; GENE SILENCING; GENE TARGETING; HISTONE MODIFICATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; NUCLEOTIDE SEQUENCE; POSITIVE FEEDBACK; PRIORITY JOURNAL; PROTEIN TARGETING; RECEPTOR DOWN REGULATION; UPREGULATION;

EID: 84867606040     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2023.05.003     Document Type: Erratum

References (23)

1. Chang T.C., Yu D., Lee Y.S., Wentzel E.A., Arking D.E., West K.M., Dang C.V., Thomas-Tikhonenko A., Mendell J.T. Widespread microRNA repression by Myc contributes to tumorigenesis. Nat. Genet. 2008, 40:43-50.
2. Chen H., Tu S.W., Hsieh J.T. Down-regulation of human DAB2IP gene expression mediated by polycomb Ezh2 complex and histone deacetylase in prostate cancer. J. Biol. Chem. 2005, 280:22437-22444.
3. Dave S.S., Fu K., Wright G.W., Lam L.T., Kluin P., Boerma E.J., Greiner T.C., Weisenburger D.D., Rosenwald A., Ott G., et al. Molecular diagnosis of Burkitt's lymphoma. N. Engl. J. Med. 2006, 354:2431-2442. Lymphoma/Leukemia Molecular Profiling Project.
4. Fabbri M., Garzon R., Cimmino A., Liu Z., Zanesi N., Callegari E., Liu S., Alder H., Costinean S., Fernandez-Cymering C., et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc. Natl. Acad. Sci. USA 2007, 104:15805-15810.
5. Fabbri M., Croce C.M. Role of microRNAs in lymphoid biology and disease. Curr. Opin. Hematol. 2011, 18:266-272.
6. Fiskus W., Wang Y., Sreekumar A., Buckley K.M., Shi H., Jillella A., Ustun C., Rao R., Fernandez P., Chen J., et al. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. Blood 2009, 114:2733-2743.
7. Hartmann E., Fernàndez V., Moreno V., Valls J., Hernández L., Bosch F., Abrisqueta P., Klapper W., Dreyling M., Hoster E., et al. Five-gene model to predict survival in mantle-cell lymphoma using frozen or formalin-fixed, paraffin-embedded tissue. J. Clin. Oncol. 2008, 26:4966-4972.
8. Kota J., Chivukula R.R., O'Donnell K.A., Wentzel E.A., Montgomery C.L., Hwang H.W., Chang T.C., Vivekanandan P., Torbenson M., Clark K.R., et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 2009, 137:1005-1017.
9. Kurland J.F., Tansey W.P. Myc-mediated transcriptional repression by recruitment of histone deacetylase. Cancer Res. 2008, 68:3624-3629.
10. Liu S., Wu L.C., Pang J., Santhanam R., Schwind S., Wu Y.Z., Hickey C.J., Yu J., Becker H., Maharry K., et al. Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia. Cancer Cell 2010, 17:333-347.
11. Lu J., He M.L., Wang L., Chen Y., Liu X., Dong Q., Chen Y.C., Peng Y., Yao K.T., Kung H.F., Li X.P. MiR-26a inhibits cell growth and tumorigenesis of nasopharyngeal carcinoma through repression of EZH2. Cancer Res. 2011, 71:225-233.
12. Mott J.L., Kobayashi S., Bronk S.F., Gores G.J. mir-29 regulates Mcl-1 protein expression and apoptosis. Oncogene 2007, 26:6133-6140.
13. Nilsson J.A., Cleveland J.L. Myc pathways provoking cell suicide and cancer. Oncogene 2003, 22:9007-9021.
14. Pekarsky Y., Santanam U., Cimmino A., Palamarchuk A., Efanov A., Maximov V., Volinia S., Alder H., Liu C.G., Rassenti L., et al. Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181. Cancer Res. 2006, 66:11590-11593.
15. Sander S., Bullinger L., Klapproth K., Fiedler K., Kestler H.A., Barth T.F., Möller P., Stilgenbauer S., Pollack J.R., Wirth T. MYC stimulates EZH2 expression by repression of its negative regulator miR-26a. Blood 2008, 112:4202-4212.
16. Slack G.W., Gascoyne R.D. MYC and aggressive B-cell lymphomas. Adv. Anat. Pathol. 2011, 18:219-228.
17. So A.Y., Jung J.W., Lee S., Kim H.S., Kang K.S. DNA methyltransferase controls stem cell aging by regulating BMI1 and EZH2 through microRNAs. PLoS One 2011, 6:e19503.
18. Sparmann A., van Lohuizen M. Polycomb silencers control cell fate, development and cancer. Nat. Rev. Cancer 2006, 6:846-856.
19. van Haaften G., Dalgliesh G.L., Davies H., Chen L., Bignell G., Greenman C., Edkins S., Hardy C., O'Meara S., Teague J., et al. Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat. Genet. 2009, 41:521-523.
20. van Kemenade F.J., Raaphorst F.M., Blokzijl T., Fieret E., Hamer K.M., Satijn D.P., Otte A.P., Meijer C.J. Coexpression of BMI-1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma. Blood 2001, 97:3896-3901.
21. Visser H.P., Gunster M.J., Kluin-Nelemans H.C., Manders E.M., Raaphorst F.M., Meijer C.J., Willemze R., Otte A.P. The Polycomb group protein EZH2 is upregulated in proliferating, cultured human mantle cell lymphoma. Br. J. Haematol. 2001, 112:950-958.
22. Zhang X., Chen X., Lin J., Lwin T., Wright G., Moscinski L.C., Dalton W.S., Seto E., Wright K., Sotomayor E., Tao J. Myc represses miR-15a/miR-16-1 expression through recruitment of HDAC3 in mantle cell and other non-Hodgkin B-cell lymphomas. Oncogene 2012, 31:3002-3008.
23. Zhao J.J., Lin J., Lwin T., Yang H., Guo J., Kong W., Dessureault S., Moscinski L.C., Rezania D., Dalton W.S., et al. microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma. Blood 2010, 115:2630-2639.